{"classes":[{"categories":[{"measurements":[{"comment":"No data are available due to low event rate in the population.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No data are available due to low event rate in the population.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No data are available due to low event rate in the population.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No data are available due to low event rate in the population.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No data are available due to low event rate in the population.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No data are available due to low event rate in the population.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"PFS was calculated as time from first dose of investigational product date to disease progression date or death due to any cause, whichever was earlier.\n\nPFS time in months: (date of disease progression or death - first dose date +1)/30.4.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RR MM and/or NHL received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG000","title":"Part 1a: 80 mg AMG 397"},{"description":"Participants with RR MM and/or NHL received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG001","title":"Part 1a: 160 mg AMG 397"},{"description":"Participants with RR MM received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG002","title":"Part 1a: 320 mg AMG 397"},{"description":"Participants with RR AML received 80 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG003","title":"Part 1b: 80 mg AMG 397"},{"description":"Participants with RR AML received 160 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG004","title":"Part 1b: 160 mg AMG 397"},{"description":"Participants with RR AML received 320 mg AMG 397 QD2, as part of a 28-day treatment cycle.\n\nParticipants could receive AMG 397 until the participant became intolerant to the investigational product, signs and symptoms of clinical progression were evident as determined by the investigator, or the participant withdrew consent.","id":"OG005","title":"Part 1b: 320 mg AMG 397"}],"paramType":"MEDIAN","populationDescription":"Parts 2 and 3 were not initiated and did not enrol any participants, therefore results presented only included participants in part 1. Per the statistical analysis plan (SAP), PFS was only to be calculated if the number of participants who experienced events (disease progression or death) was 10 or more in either part 1 or part 2.\n\nFAS: All participants who were enrolled and received at least 1 dose of AMG 397.","reportingStatus":"POSTED","timeFrame":"Up to end of study (a maximum of 48 weeks)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}